Portal de Periódicos da CAPES

Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?

2022; SAGE Publishing; Volume: 28; Issue: 7 Linguagem: Inglês

10.1177/13524585221089540

1477-0970

Ana Zabalza, Georgina Arrambide, Susana Otero‐Romero, Agustín Pappolla, Paula Tagliani, Samuel López‐Maza, Simón Cárdenas‐Robledo, Juliana Esperalba, Candela Fernández‐Naval, Mónica Martínez‐Gallo, Mireia Castillo, Mercè Bonastre, M. Resina-Salles, Jordina Bertran, Marta Rodríguez‐Barranco, Pere Carbonell‐Mirabent, Marina González, Miguel Á. Merchán, Ana Quiroga‐Varela, Albert Miguela, Imma Gómez, Gary Álvarez, René Carlos Calderón Robles, Dúnia Pérez del Campo, Xavier Queralt, María José Soler, Irene Agraz, Fernando Martínez‐Valle, Breogán Rodrı́guez‐Acevedo, Luciana Midaglia, Ángela Vidal‐Jordana, Álvaro Cobo‐Calvo, Carmen Tur, Ingrid Galán, Joaquín Castilló, Jordi Río, Carmen Espejo, Manuel Comabella, Carlos Nos, Jaume Sastre‐Garriga, Lluís Ramió‐Torrentà, Mar Tintoré, Xavier Montalbán,

Immunotherapy and Immune Responses

The effect of disease-modifying therapies on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response is unclear.We aim to determine the immunological responses to SARS-CoV-2 in multiple sclerosis (MS) and anti-CD20-treated patients with other autoimmune diseases (AID).Humoral and cellular responses we determined before and 30-90 days after vaccination in patients with MS and anti-CD20-treated patients with other AID in two Catalan centers.457 patients were enrolled. Findings showed that humoral response decreased under anti-CD20s or sphingosine 1-phosphate receptor modulators (S1PRM) and with longer treatment duration and increased after 4.5 months from the last anti-CD20 infusion. Cellular response decreased in S1PRM-treated. Patients on anti-CD20 can present cellular responses even in the absence of antibodies.Anti-CD20s and S1PRM modify the immunological responses to SARS-CoV-2 vaccines.